Trademark: 88377819
Word
MIQURE
Status
Registered
Status Code
700
Status Date
Tuesday, June 1, 2021
Serial Number
88377819
Registration Number
6367204
Registration Date
Tuesday, June 1, 2021
Mark Type
4000
Filing Date
Tuesday, April 9, 2019
Published for Opposition
Tuesday, March 16, 2021

Trademark Owner History
uniQure IP B.V. - Original Registrant

Classifications
5 Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; Pharmaceutical preparations and substances for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases
44 Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics
42 Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics

Trademark Events
May 26, 2023
Teas Withdrawal Of Attorney Received-Firm Retains
May 26, 2023
Teas Change Of Correspondence Received
May 26, 2023
Teas Change Of Domestic Representatives Address
May 26, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
May 26, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 26, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
May 26, 2023
Teas Change Of Owner Address Received
Jun 1, 2021
Registered-Principal Register
Mar 16, 2021
Official Gazette Publication Confirmation E-Mailed
Mar 16, 2021
Published For Opposition
Feb 24, 2021
Notification Of Notice Of Publication E-Mailed
Feb 8, 2021
Electronic Record Review Complete
Feb 5, 2021
On Hold - Electronic Record Review Required
Feb 2, 2021
Approved For Pub - Principal Register
Feb 2, 2021
Examiner's Amendment Entered
Feb 2, 2021
Notification Of Examiners Amendment E-Mailed
Feb 2, 2021
Examiners Amendment E-Mailed
Feb 2, 2021
Examiners Amendment -Written
Jan 28, 2021
Suspension Checked - To Attorney For Action
Jun 11, 2020
Report Completed Suspension Check Case Still Suspended
Dec 5, 2019
Notification Of Letter Of Suspension E-Mailed
Dec 5, 2019
Letter Of Suspension E-Mailed
Dec 5, 2019
Suspension Letter Written
Dec 4, 2019
Teas/Email Correspondence Entered
Dec 4, 2019
Correspondence Received In Law Office
Dec 4, 2019
Assigned To Lie
Nov 25, 2019
Teas Response To Office Action Received
Jun 24, 2019
Notification Of Non-Final Action E-Mailed
Jun 24, 2019
Non-Final Action E-Mailed
Jun 24, 2019
Non-Final Action Written
Jun 19, 2019
Assigned To Examiner
Apr 25, 2019
New Application Office Supplied Data Entered
Apr 12, 2019
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24